Veru Inc (VERU)
NASDAQ:VERU
Want to see VERU full AI Analyst Report?
Top Page
Veru
(NASDAQ:VERU)
Select Model
Select Model
Rating:51Neutral
Price Target:
$3.50
▲(43.44% Upside)
Action:Reiterated
Date:06/06/26
The score is held down primarily by very weak financial performance (minimal/volatile revenue, large losses, and persistent cash burn). Offsetting factors include improving clinical momentum and liquidity commentary from the earnings call, plus a supportive Novo Nordisk supply agreement, while technicals show strong trend strength but with overbought risk.
Positive Factors
Clinical efficacy evidence
Statistically robust functional results demonstrate enobosarm can preserve lean mass and physical function when added to a GLP‑1. This strengthens the product rationale versus GLP‑1 monotherapy, supports regulatory pathways focused on function/BMD, and increases the program's long‑term clinical credibility and partner appeal.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow indicate the company consumes substantial capital to advance trials. With no positive FCF and historical large outflows, Veru will likely need additional financing for full pivotal development, risking dilution and constraining strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy evidence
Statistically robust functional results demonstrate enobosarm can preserve lean mass and physical function when added to a GLP‑1. This strengthens the product rationale versus GLP‑1 monotherapy, supports regulatory pathways focused on function/BMD, and increases the program's long‑term clinical credibility and partner appeal.
Read all positive factors
Veru (VERU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$67.89M
Dividend YieldN/A
Average Volume (3M)62.21K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue Growth-100.00%
EPS Growth63.20%
CountryUS
Employees210
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.80
Shares Outstanding16,050,320
10 Day Avg. Volume64,687
30 Day Avg. Volume62,212
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.04
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-154.20
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$25.00Price Target Upside924.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.19
Revenue Forecast (FY)N/A
Veru Business Overview & Revenue Model
Company Description
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transm...
How the Company Makes Money
Veru’s business model is primarily research-and-development driven, with revenue historically coming from (i) net product revenue from any marketed products it sells and (ii) other income such as licensing, collaboration, or royalty-related arrang...
Veru Earnings Call Summary
Earnings Call Date:May 13, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call reported meaningful clinical progress (positive Phase IIb functional results, active enrollment in a pivotal-feeding Phase IIb plateau study with interim readout expected Q1 2027) and materially improved near-term liquidity and expense trends. At the same time, Veru remains unprofitable, faces label and regulatory complexity (possible need for agent-specific studies or function/BMD endpoints), stiff competition from established GLP-1 players, and dependence on nonrecurring gains and an interim milestone for runway. On balance, the progress on clinical endpoints, the clear regulatory strategy contingencies, and improved cash position outweigh the operational and regulatory risks discussed.Positive Updates
Positive Phase IIb 'quality' study results on physical function
Enobosarm plus semaglutide demonstrated preservation of lean mass and physical function versus semaglutide alone. Enobosarm 3 mg + semaglutide produced a 59.8% relative reduction in the proportion of patients with ≥10% decline in stair-climb power versus placebo+semaglutide (p=0.0006). Enobosarm 6 mg + semaglutide produced a 44.1% relative reduction (p=0.051).
Negative Updates
Company remains unprofitable with negative cash flows historically
Veru is not profitable and has had negative cash flows from operations historically. Although cash improved, future funding requirements remain tied to clinical progress and may require additional financing beyond current runway.
Read all updates
Q2-2026 Updates
Positive
Negative
Positive Phase IIb 'quality' study results on physical function
Enobosarm plus semaglutide demonstrated preservation of lean mass and physical function versus semaglutide alone. Enobosarm 3 mg + semaglutide produced a 59.8% relative reduction in the proportion of patients with ≥10% decline in stair-climb power versus placebo+semaglutide (p=0.0006). Enobosarm 6 mg + semaglutide produced a 44.1% relative reduction (p=0.051).
Read all positive updates
Company Guidance
The company guided that the Phase IIb "Plateau" study (≈200 patients, age ≥65, BMI ≥35) enrolled its first patient on March 9, 2026 and is designed with a 68‑week primary endpoint (percent change in total body weight) and an interim analysis at 36 weeks to assess percent change in lean body mass and total fat mass by DXA, with the 36‑week interim results expected in Q1 calendar 2027; this builds on the positive Phase IIb “Quality” trial (168 patients ≥60 years, enobosarm 3 mg and 6 mg vs placebo on semaglutide, 16‑week active treatment + 12‑week extension) that showed a prespecified responder analysis (≥10% decline in stair‑climb power) with placebo+semaglutide at 44.3% affected, enobosarm 3 mg yielding a 59.8% relative reduction (p=0.0006) and enobosarm 6 mg a 44.1% relative reduction (p=0.051); management reiterated the rationale (addressing the GLP‑1 nonselective loss of lean mass and the 88% one‑year weight‑loss plateau, with SURMOUNT‑1 noting 62.6% remain clinically obese at plateau), highlighted the large market opportunity (>1 billion with obesity worldwide; WHO: 2.5 billion overweight/obese; ~30 million U.S. with obesity + low muscle mass; 41.5% obesity prevalence in ≥65 among 47.4M Medicare Part D ≈20M patients), and confirmed financials to support the program (cash $27.6M as of March 31, 2026; net working capital $28M; net proceeds from Oct 31, 2025 offering ≈$23.4M) with R&D $3.1M in the quarter ($4.5M six months), SG&A $4.1M quarter ($8.2M six months), cash used in operations $15.1M (six months), and management’s view that existing cash is sufficient to fund operations beyond the planned interim analysis.Veru Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 16.89M | 16.30M | 39.35M | 61.26M |
| Gross Profit | -86.10K | -152.10K | 5.85M | 7.57M | 30.59M | 47.93M |
| EBITDA | -28.02M | -35.38M | -36.20M | -89.98M | -79.23M | 9.75M |
| Net Income | -14.10M | -22.73M | -37.80M | -93.15M | -83.78M | 7.39M |
Balance Sheet | ||||||
| Total Assets | 43.08M | 29.84M | 60.42M | 50.02M | 135.36M | 178.15M |
| Cash, Cash Equivalents and Short-Term Investments | 30.76M | 18.32M | 24.92M | 9.63M | 80.19M | 122.36M |
| Total Debt | 2.83M | 3.12M | 13.86M | 14.41M | 15.88M | 13.74M |
| Total Liabilities | 8.30M | 11.50M | 28.10M | 30.34M | 52.56M | 25.85M |
| Stockholders Equity | 34.79M | 18.33M | 32.32M | 19.68M | 82.80M | 152.29M |
Cash Flow | ||||||
| Free Cash Flow | -26.06M | -30.04M | -21.84M | -88.68M | -48.24M | -15.95M |
| Operating Cash Flow | -26.06M | -30.04M | -21.68M | -88.01M | -47.51M | -15.57M |
| Investing Cash Flow | 10.27M | 25.14M | 146.21K | 6.33M | 4.27M | 14.62M |
| Financing Cash Flow | 23.37M | -4.22M | 36.83M | 11.11M | 1.07M | 109.72M |
Veru Technical Analysis
Positive
2.44
Price Trends
2.34
Positive
2.40
Positive
2.75
Positive
Market Momentum
0.16
Negative
87.85
Negative
56.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VERU, the sentiment is Positive. The current price of 2.44 is above the 20-day moving average (MA) of 2.35, above the 50-day MA of 2.34, and below the 200-day MA of 2.75, indicating a bullish trend. The MACD of 0.16 indicates Negative momentum. The RSI at 87.85 is Negative, neither overbought nor oversold. The STOCH value of 56.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VERU.
Veru Risk Analysis
Veru disclosed 58 risk factors in its most recent earnings report. Veru reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Veru Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $124.50M | -7.25 | -98.30% | ― | 309.60% | 72.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $67.89M | -5.22 | -53.43% | ― | -100.00% | 63.20% | |
51 Neutral | $205.55M | -1.03 | 77.87% | ― | 6.33% | -102.63% | |
50 Neutral | $35.89M | -0.81 | -170.86% | ― | -100.00% | 13.12% | |
45 Neutral | $28.80M | -0.24 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
VERU
Veru
3.40
-2.78
-44.98%
KPTI
Karyopharm Therapeutics
9.08
4.59
102.23%
CUE
Cue Biopharma
29.46
10.23
53.20%
INMB
Inmune Bio
1.26
-6.36
-83.46%
CELU
Celularity
0.87
-1.21
-58.08%
JUNS
Jupiter Neurosciences, Inc.
0.24
-0.54
-68.97%
Veru Corporate Events
Business Operations and StrategyProduct-Related Announcements
Veru, Novo Nordisk partner on enobosarm-Wegovy trial
Positive
Jun 4, 2026
On June 2, 2026, Veru Inc. entered into a clinical supply agreement with Novo Nordisk to support Veru’s Phase 2b PLATEAU trial evaluating enobosarm in combination with Novo Nordisk’s obesity drug Wegovy in older adults receiving Wegovy...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Veru Shareholders Expand Equity Plan, Reelect Board Leadership
Neutral
Mar 13, 2026
At its 2026 Annual Meeting of Shareholders held on March 12, 2026, Veru Inc. won investor approval to significantly expand its 2018 Equity Incentive Plan, more than doubling the pool of common shares available for awards from 2.6 million to 5.85 m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.